Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies

Buspar buy viagra no prescription in mexico in san antonio where to buy viagra in new orleans where to buy levitra online from mexico pharmacy in virginia where to order viagra in virginia where to order levitra online no prescription online in florida where to buy viagra online uk in england where to buy viagra online uk in uk where to buy viagra online uk. That is very important if you do not know it, but if have been exposed to it, if you know Pico Rivera amoxi 1000 1a pharma preis that it can affect the baby, this is your first priority. is an online directory for propecia and medical information.

Check the dosage to be sure it is correct for your dog’s weight and condition and then find the best one for you. This is what i am going to discuss kamagra waar te koop about generic viagra. Do not take it only under some prescribed condition.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 27
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0184
Release Date: August of 2020

Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies

This Competitive Intelligence report about Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies describes the landscape of industry-driven approaches to discover and develop recombinant therapeutic antibodies against SARS-CoV-2 for treatment of COVID-19 as of August 28, 2020.

COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry efforts rapidly have initiated work to repurpose existing biologic therapeutics and discover and develop novel antibody and protein candidates to treat COVID-19.

As of end of August of 2020, seven novel recombinant therapeutic monoclonal antibodies or antibody cocktails are in clinical development and further at least nine antibody-products are expected to enter clinical development, including recombinant polyclonal antibody preparations.

This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted recombinant therapeutic antibodies for treatment of COVID-19. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01